Home Featured Page 32

Featured

Latest

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It

Pα+ Psychedelic Bulletin #210: Compass Exec Defends Minimal Support Model in...

Mary Carreón — Censorship, Psychedelic Media & Policy Crosscurrents

Joe & Kyle Catch-Up: Vital Cohort 4, Breathwork, Community & a...

Greg Shanken — Collaborence, Community Access & Ethical Growth in Psychedelics

Pα+ Psychedelic Bulletin #209: Aussie Insurer Covers Psilocybin for TRD; atai...

Dr. Cat Meyer – Sex, Love, Psychedelics

Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase...

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But...

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

EDITOR PICKS

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It

Pα+ Psychedelic Bulletin #210: Compass Exec Defends Minimal Support Model in...

Mary Carreón — Censorship, Psychedelic Media & Policy Crosscurrents

Joe & Kyle Catch-Up: Vital Cohort 4, Breathwork, Community & a...

Greg Shanken — Collaborence, Community Access & Ethical Growth in Psychedelics

Pα+ Psychedelic Bulletin #209: Aussie Insurer Covers Psilocybin for TRD; atai...

Dr. Cat Meyer – Sex, Love, Psychedelics

Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase...

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But...

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

EDITOR PICKS

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY